Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer
- Conditions
- Relapsed or Refractory Solid TumorsNonsmall Cell Lung Cancer
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2021-12-30
- Lead Sponsor
- Fox Chase Cancer Center
- Target Recruit Count
- 3
- Registration Number
- NCT02963610
- Locations
- 🇺🇸
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin Lymphoma
- Conditions
- Lymphoma, Non-Hodgkin
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2022-02-18
- Lead Sponsor
- Millennium Pharmaceuticals, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02954406
- Locations
- 🇺🇸
West Virginia University, Morgantown, West Virginia, United States
🇺🇸Cedars-Sinai Medical Center (CSMC) - Samuel Oschin Comprehensive Cancer Institute, West Hollywood, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Tucson, Arizona, United States
Topical Proparacaine Eye Drops to Improve the Experience of Patients Undergoing Intravitreal Injections
- Conditions
- Age-related Macular DegenerationInjection SiteDiabetic Macular EdemaInjection Site InfectionPain, Postoperative
- Interventions
- Procedure: Conjunctival cultureDrug: Proparacaine
- First Posted Date
- 2016-11-01
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 36
- Registration Number
- NCT02951351
- Locations
- 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
High Dose Carfilzomib for Newly Diagnosed Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-10-18
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 37
- Registration Number
- NCT02937571
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
Efficacy of Eltrombopag Plus Lenalidomide Combination Therapy in Patients With IPSS Low and Intermediate-risk Myelodysplastic Syndrome With Isolated del5q
- Conditions
- Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2016-10-10
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Associazione Qol-one
- Target Recruit Count
- 2
- Registration Number
- NCT02928419
- Locations
- 🇫🇷
CHU d'Angers, Angers, France
🇫🇷Centre Henri Mondor, Creteil, France
🇫🇷Centre de Marseille, Marseille, France
Comparing Ropivacaine and Bupivacaine in DTFNB Anesthesia in Patients Undergoing Phacoemulsification
- Conditions
- Cataract Unilateral Pending ExtractionAnesthesia
- Interventions
- Procedure: Deep Topical Fornix Nerve block anesthesiaDrug: BupivacaineDrug: RopivacaineDrug: Proparacaine
- First Posted Date
- 2016-10-06
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Government Medical College, Haldwani
- Target Recruit Count
- 100
- Registration Number
- NCT02925832
- Locations
- 🇮🇳
Government medical college, Haldwani, Uttarakhand, India
Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome
- Conditions
- PlasmacytomaPOEMS Syndrome
- Interventions
- First Posted Date
- 2016-10-03
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 21
- Registration Number
- NCT02921893
- Locations
- 🇺🇸
Mayo Clinic in Rochester, Rochester, Minnesota, United States
A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2020-04-03
- Lead Sponsor
- Janssen Pharmaceutical K.K.
- Target Recruit Count
- 7
- Registration Number
- NCT02918331
A Study of Ixazomib Plus Lenalidomide and Dexamethasone in Adult Japanese Participants With Relapsed and/or Refractory Multiple Myeloma
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-28
- Last Posted Date
- 2021-01-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 34
- Registration Number
- NCT02917941
Trial of Combination of Ixazomib and Lenalidomide and Dexamethasone in Smoldering Multiple Myeloma
- Conditions
- Smoldering Multiple Myeloma
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 55
- Registration Number
- NCT02916771
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.